Investigation of a new paclitaxel nano niosomal formulation and biological evaluation of entrapped paclitaxel on breast cancer cell line
,1,* Javad zavvar reza
,2 Hossein zarei jaliani
,3 Fateme haghiralsadat
1. Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2. Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3. Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4. Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, Iran
Regarding that the breast adenocarcinoma is the most widespread disease among women, paclitaxel, an anti-cancer drug, could be used in treatment of this cancer. paclitaxel side effects are bone marrow suppression and peripheral neuropathy. recently, it has been shown that nanotechnology can be used to further decrease side effects, enhancement the efficiency of treatment. niosomes are one of the nanocarriers for drug delivery. in this study paclitaxel nanoniosomal with the thin film hydration method was prepared. aim of this study is use of nanoniosomal containing paclitaxel and cytotoxic effects on breast cancer cell lines.
In the current study, paclitaxel nanoniosomal formulation was prepared by the thin-film hydration method. the characterization tests of dynamic light scattering (dls) and uv-vis spectrophotometry were utilized to evaluate the quality of the nanoniosome. tween 60 and cholesterol were obtained from lipoid gmbh. in addition, the mtt cell proliferation assay was used on mcf-7 cell lines to determine cell viability. mcf-7 cells were obtained from the iranian biological resource center (tehran, iran).
We observed an entrapment efficiency of 98.79 % for paclitaxel within the optimized niosomal formulation that had a niosomal diameter of 119.7 nm. polydispersity index and zeta potentials of optimum formulation were 0.203 and -4, respectively. the ic50 value of free paclitaxel solution was 13.54 ± 0.28 μg/ml against mcf-7 cells whereas the ic50 value of paclitaxel niosomal was 3.73 ± 0.29. this revealed that nanoniosome was highly efﬁcient in delivering the paclitaxel drug to mcf-7 cells.
Our studies achieved successful formulation of paclitaxel niosomal thus indicating that nanoparticle-based formulation of paclitaxel has high potential as an adjuvant therapy for clinical application in breast cancer.
Niosome, paclitaxel, nanotechnology, breast cancer